Clinic Disorders Homecare Patient associations Funding arrangements Research and publications Contacts

Current clinical trials at Addenbrooke's | Key publications

 

At Addenbrooke's we are always looking to improve both the quality of care and the treatment options available to all our patients. We are actively involved in both academic and clinical research, funded independently and in conjunction with our partners in the pharmaceutical industry.

 

From time to time there may be the opportunity for patients to participate in these studies and your physician will let you know whether it is suitable for you.

Current clinical trials at Addenbrooke's

Fabry

 

Currently none - watch this space.

 

---

 

Gaucher

 

 

Zavesca switch study

This is a Phase 3b multi centre study sponsored by the pharmaceutical company Actelion. Miglustat (Zavesca) is a tablet treatment currently licensed for use in Gaucher disease. This study is looking at whether stable type 1 Gaucher patients continue to remain stable when switched to Zavesca for a period of  2 years.

 

Current status: recruitment finished. Study to report in March 2010

 > Actelion - Miglustat (Zavesca®) in Clinical Development

 

 

 

AT2101 naïve study

 

This is a Phase 2 multi centre study sponsored by the pharmaceutical company Amicus. Plicera (AT2101) is a new (unlicensed) tablet  treatment. This study is looking at safety and side effects in treatment naïve patients (ie patients who have not received ERT/SRT) with type 1 Gaucher disease. It is also hoped to see some efficacy in managing disease/symptoms. This treatment is thought to work as a pharmacological chaperone rather than as with Enzyme replacement therapy (ERT) or Substrate reduction therapy (SRT) and the intention is to treat eligible patients with AT2101 for about 6 months.

 

> Amicus Therapeutics

Current status: recruitment finished - study due to report late 2009

> Plicera™ (AT2101) for Gaucher Disease

 

 

 

Coming soon - other tablet and intravenous treatments

 

Watch this space

 

---

 

Pompe

 

Currently none - watch this space.

 

---

 

Trials taking place elsewhere:

 

Fabry

Studies underway - Amicus therapeutics Phase II studies Amigal (tablet)

 

> Amigal™ for Fabry Disease

 

---

 

Gaucher

Shire - Phase 3  study GA-GCB (infusion) for treatment naïve - not  participating but other UK centres may be.
> Shire - Research and Development Projects

 

 

---

 

Pompe

Amicus - AT2220 (tablet treatment) - currently in phase 1 studies

> Amicus - AT2220 for Pompe Disease

> Research and Development at Genzyme

 

---

 

Genzyme research phases

> An Introduction to the Clinical Research Process

 

---

 

Future clinical trials

 

Genzyme

Phase 3 study Genz 112638 (tablet) - planning stages - more details to follow

 

Protalix - prGCD (infusion) studies in planning stages for both naïve and switch/maintenance studies (another form of ERT) - more details to follow

 

> Protalix Biotherapeutics

 

 

Other research

 

 

Bone project

A multi centre UK  adult/children study looking at progression and features of Gauchers disease including its effects on mobility and quality of life. recruitment now completed – report writing /analysis ongoing.

Funded by the Gaucher Association

 

 

 

Gene therapy in mouse model of Sandhoff disease  

Progress continues

> Professor Timothy Cox - Department of Medicine, University of Cambridge

 

 

 

Genetic Variation of LIMP-2 in neuronopathic Gaucher Disease

 

This is a multi centre UK study coordinated by Dr Nick Smith looking at genetic changes in LIMP -2 – a modifier gene thought to be associated with Gaucher disease. The intention is to compare findings between those who have neurology symptoms with those who do not. Recruitment will be starting imminently.  If you would like to know more please contact us.

> Contact us

 

 

 

International, multicentre, long term observational database studies

• FOS & HOS (Fabry & Hunter Outcome surveys  - Shire) 
• Genzyme registries (Gaucher, Fabry & Pompe),
• IS3 safety surveillance program (Zavesca - Actelion)

 

 

Penninsular Medical School/HTA project

 

> A longitudinal cohort study of people with lysosomal storage disorders  

The Peninsula Medical School, in collaboration with the treatment centres and the support groups, is looking at how effective and cost effective therapies for lysosomal disorders are. 

 

 

 

Therapeutic targeting of enzyme glycoforms in Fabry and Hunter 

MPS society funded research

Patient recruitment continues (Cambridge study only).

This study is looking at how therapy gets to where it is needed and whether this can be improved.

 

 

 

 

Research interests

 

We work closely with Professor Cox's team in the university department of medicine:

> Professor Timothy Cox - Department of Medicine, University of Cambridge

The broad aim of our scientific studies is to improve the diagnosis, monitoring and treatment of lysosomal disorders: we thus investigate the natural course and molecular pathogenesis of these diseases; we have discovered novel biomarkers and have introduced innovative treatments. As part of the latter, a gene transfer programme has been initiated; this involves pre clinical research designed to translate our recent therapeutic discoveries rapidly from the laboratory to the clinic.

Some of our current research interests include:

• Biomarkers of disease
• Pathogenesis of Gaucher disease
• Gene therapy - with a specific interest in the Lysosomal storage disorders that cause neurological disease
  
  

 

Key publications

 

Professor Cox

> Department of Medicine, University of Cambridge - Professor Cox

• Mistry, P.K., Wraight, E.P. and Cox, T.M. (1996)
  Delivery of proteins to macrophages: implications for treatment of Gaucher Disease.  Lancet 348: 1555-1559.
  
  
• Moran, MT, Schofield J., Hayman A.R., E. Young, Shi G-P and Cox T.M. (2000) Pathologic gene expression in Gaucher’s disease with upregulation of cysteine proteinases including osteoclastic Cathepsin K. Blood 56: 1969-1978.
  
  
• Cox, T.M. (2001) Gaucher’s disease: understanding the molecular pathogenesis of sphingolipidoses. Journal of Inherited Metabolic Disease 24: (suppl.2): 97-105.Boot R.G., Verhoek M., de Cost M, Hollak CE, Maas M, Bleijtevens B., Van Breemen  MJ. van Meurs M., Boven LA., Laman JD., Moran MT, Cox TM.,  Aerts JM (2004)  Marked elevation of the chemokine CCL18/PARC in Gaucher disease: a novel surrogate  marker for assessing therapeutic intervention. Blood 103: 33-39.
  
  
• Deegan, PB., Moran, M-T., McFarlane, I., Schofield, JP., Boot, RG.,      Aerts, JMFG., and Cox, TM. (2005) Clinical evaluation of chemokine and enzymatic biomarkers of Gaucher disease. Blood Cells, Molecules and Disease 35:259-267
  
  
• Cox T., Lachmann R., Hollak C., Aerts J., van Weely S., Hrebicek M., Platt F., Butters T., Dwek R., Moyses C., Gow I., Elstein D., Zimran A. (2000)  A Novel Oral Treatment of Gaucher’s Disease with N- butyldeoxynojirimycin (OGT 918) to decrease Substrate Biosynthesis.  Lancet 355: 1481-1485
  
  
• Elstein D., Hollak C., Aerts JM, van Weely S., Maas M., Cox T.M.,  Lachmann RH., Hrebicek M., Platt FM., Butters TD., Dwek RA, Zimran      A (2004)  Sustained  therapeutic effects of oral miglustat (Zavesca, N-     butyldeoxynojirimycin, OGT 918) in  type 1 Gaucher disease. Journal of Inherited Metabolic Disease 27: 757-766.
  
  
• Lachmann, RH, te Vruchte, D., Lloyd-Evans E, Reinkensmeier G, Sillence DJ, Fernandez-Guillen L., Dwek RA., Butters TD, Cox TM, Platt FM (2004)  Treatment with miglustat reverses the lipid-trafficking defect in Niemann-Pick disease type C. Neurobiology of Disease 16: 654-658.
  
  
• Whitfield PD., Calvin J, Hogg S, O’Driscoll E., Halsall D., Burling K., Maguire G., Wright N., Cox TM, Meikle PJ.,and  Deegan, PB. (2005) Monitoring enzyme replacement therapy in Fabry disease – role of urine globotriasoylceramide. Journal of Inherited Metabolic Disease 28: 21-33.
  
  
• Cachón-González M.B., Wang S.Z., Lynch A., Ziegler R., Cheng, SH &  Cox, TM. (2006) Effective gene therapy in an authentic model of Tay-Sachs related diseases. Proceedings of the National Academy of Sciences (USA) 103: 10373-10378.
  
  
• Cox, T.M., Platt, F.M. and Aerts, J.M.F.G. (2007)
  Medicinal Use of Iminosugars Chapter 13, in:
  Iminosugars from Synthesis to Therapeutic Applications
  pp.295-328. Edited P. Compain & O. Martin, Wiley, Chichester, UK.
  
  
• Cox, T.M. (2008) Gaucher’s Disease. A Model Disorder for
  Therapeutic Exploration of the Lysosome, in: Mechanisms of
  Disease, Edited by S.Tomlinson, A.M. Heagarty, A.P. Weetman,
  R.A. Malik, 2nd edition, Cambridge University Press, pp.42-68.
  
  
• Chen Y, Allegood J, Liu Ying, Wang E, Cachón-González MB,
  Cox TM, Merrill A, Sullards M. (2008) Imaging MALDI Mass Spectrometry Using an Oscillating Capillary Nebulizer Matrix Coating System and Its Application to Analysis of Lipid in Brain from a Mouse Model of Tay-Sachs/Sandhoff Disease. Analytical Chemistry e-pub 4 March
  
  
• Cox, T.M. Aerts, J.M.F.G., Belmatoug, N., Capellini, M.D.,
  vom Dahl, S., Goldblatt, J., Grabowski, G.A., Hollak, C.E.M.,
  Hwu, P., Maas, M., Martins, A.M., Mistry, P.K., Pastores, G.M.,
  Tylki-Szymanska, A., Yee, J. and  Weinreb, N. (2008)
  Management of non-neuronopathic Gaucher disease with
  special reference to pregnancy, splenectomy, bisphosphonate therapy, use of biomarkers and bone disease monitoring. Journal of Inherited Metabolic Disease 2008 Jun;31(3):319-36. Epub 2008 May 23.
  
  
• Roos, J.C.P., Lachmann, R. H.,Carpenter, R.H.S., Cox, T.M. (2008)
  Saccadic latency as an objective biomarker of cerebral injury in lysosomal storage disease. Lancet Neurology (submitted)
  
  
• Wang, S.Z., Cachón-González, M.B., Stein, P.E., Lachmann, R.H.,
  Woods, G., Corry, P.C., Wraith, J.E.,  Cox, T.M. (2008)
  Molecular analysis of the human HEXB gene in Juvenile
  Jatzkewitz-Sandhoff disease in two extended Pakistani
  pedigrees. Human Genetics (submitted)

 

 

Abstracts for presentation

 

• M. B. Cachón-González, S. Wang, R. Ziegler, S. H. Cheng & T. M. Cox (2008) Functional Outcome and Survival Correlates with Time of Gene Transfer and Viral Titres in a Mouse Model of Sandhoff Disease (Boston: Am. Soc. Hum. Gene Therapy)
  
  
• E.V. Pavlova, M.T. Moran, P.B. Deegan, T.M. Cox (2008)
  Enhanced Abundance and Processing of Cathepsin S:
  a potential Biomarker of Gaucher disease (Budapest: EWGGD)
  
  
• E.V. Pavlova, J.E. Tindall, D.A. Hughes, A.Mehta, J.E. Wraith, T.M. Cox, and P.B. Deegan (2008) Biomarkers of Avascular Necrosis in Gaucher Disease (Budapest: EWGGD)
  
  
• Deegan PB, Tindall JE, Stein PE, Mehta A, Hughes DA, Wraith JE, Waldek S, Cox TM (2008).
  Osseous Complications of Gaucher Disease: a National Survey (Paris: 4th X-LSD Meeting)
  
  
• M.B. Cachón-González, S.Z. Wang and T.M Cox (2007)
  Combination Therapy for Tay-Sachs and Related Neurodegenerative Diseases (Bilbao: Int. Soc. Sphingolipid Res.)
  
  
• Cox, T.M. (2007) Prospects for Stem-Cell and Gene Therapy for Lysosomal Storage Disorders (Porto: Treatment of Inborn Errors)
  
  
• Marchesan D, Cox TM and Deegan PB (2007)
  Mechanism of Uptake of Therapeutic Alpha Galactosidase A in Cells Relevant to Fabry Disease (Perrugia: Eur. Study Group Lysosomal Diseases)
  
  
• M.B. Cachón-Gonzaléz, S. Z Wang, R. Ziegler, S H Cheng
  and T M Cox.(2007) Successful Gene Therapy for Tay-Sachs and related Neurodegenerative Diseases (Bristol: Association of Physicians of Great Britain & Ireland)
  
  
• Lachmann RH, Wright N, Parker A, Ramaswami U, Coleman M, Roos J, Bernstein R, Gillard J, Harding S, Platt FM, Wraith E, Cox TM (2006) Substrate reduction therapy in Sandhoff disease: evidence for improvement in nervous function in patients treated with miglustat  (Japan: SSIEM J. Inherit. Metab. Dis)

 

 

 

 

 

Back to top